The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: A review of the recent literature

Clinical Medicine and Research

Volumn 4, Issue 2, 2006, Pages 138-146

  Falagas, Matthew E ^a,b,c   Kasiakou, Sofia K ^a   Tsiodras, Sotirios ^d   Michalopoulos, Argyris ^b  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acinetobacter; Colistin; Inhalation; Intensive care unit; Klebsiella; Multidrug resistant Gram negative bacteria; Nebulization; Pneumonia; Polymyxin B; Pseudomonas; Ventilator associated

Indexed keywords

COLISTIMETHATE; COLISTIN; POLYMYXIN B;

ACINETOBACTER BAUMANNII; APNEA; ATAXIA; BACTEREMIA; CLINICAL TRIAL; CONFUSION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INTENSIVE CARE; MUSCLE WEAKNESS; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; PARESTHESIA; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; VERTIGO;

AEROSOLS; ANTI-BACTERIAL AGENTS; COLISTIN; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; POLYMYXIN B; POLYMYXINS;

EID: 33745910567     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.4.2.138     Document Type: Review

References (52)

1. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005;5:24.
2. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-121.
3. Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, Vidal G, Martins G, Das Neves A, Santander O, Ramos C. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31:1058-1065.
4. Fernandez-Viladrich P, Corbella X, Corral L, Tubau F, Mateu A. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 1999;28:916-917.
5. Kasiakou SK, Rafailidis PI, Liaropoulos K, Falagas ME. Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. J Infect 2005;50:348-352.
6. Segal-Maurer S, Mariano N, Qavi A, Urban C, Rahal JJ Jr. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis 1999;28:1134-1138.
7. Fulagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-1341.
8. Fekety FR Jr, Norman PS, Cluff LE. The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med 1962;57:214-229.
9. Koyama Y, Kurosasa A, Tsuchiya A, Takakuta K. A new antibiotic "colistin" produced by spore-forming soil bacteria. J Antibiot 1950;3:457-458.
10. Nord NM, Hoeprich PD. Polymyxin B and colistin. A critical comparison. N Engl J Med 1964;270:1030-1035.
11. Yow EM, Tan E, Shane L, Schonfeld S, Abu-Nassar H. Colistin (coly-mycin) in resistant bacterial infections. A clinical appraisal. Arch Intern Med 1961;108:664-670.
12. Flanagan AD. Adverse effects of sodium colistimethate. Ann Intern Med 1971;74:143-144.
13. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-868.
14. Tallgren LG, Liewendahl K, Kuhlbaeck B. The therapeutic success and nephrotoxicity of colistin in acute and chronic nephropathies with impaired renal function. Acta Med Scand 1965;177:717-728.
15. Duncan DA. Colistin toxicity. Neuromuscular and renal manifestations. Two cases treated by hemodialysis. Minn Med 1973;56:31-35.
16. Elwood CM, Lucas GD, Muehrcke RC. Acute renal failure associated with sodium colistimethate treatment. Arch Intern Med 1966;118:326-334.
17. Lindesmith LA, Baines RD Jr, Bigelow DB, Petty TL. Reversible respiratory paralysis associated with polymyxin therapy. Ann Intern Med 1968;68:318-327.
18. Davis SD, Iannetta A, Wedgwood RJ. Activity of colistin against Pseudomonas aeruginosa: inhibition by calcium. J Infect Dis 1971;124:610-612.
19. Newton BA. The properties and mode of action of the polymyxins. Bacteriol Rev 1956;20:14-27.
20. Gough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996;64:4922-4927.
21. Suzuki H, Nemoto H, Nakamoto H, Okada H, Sugahara S, Kanno Y. Moriwaki Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther Apher 2002;6:234-240.
22. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183-190.
23. Hogardt M, Schmoldt S, Gotzfried M, Adler K, Heesemann J. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2004;54:1057-1061.
24. Coly-mycin M Parenteral (package insert). Bristol (TN): Monarch Pharmaceuticals, Inc. 2002.
25. Colomycin [package insert]. Bexley, UK: Forest Laboratories. UK Limited. 2002.
26. Polymyxin B for injection [package insert]. Bedford Laboratories, Bedford, OH 44146, 1999.
27. Promixin I MIU powder for nebuliser solution [package insert]. West Sussex, UK: Profile Pharma Limited, UK. 2003.
28. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005;25:11-25.
29. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chcmother 2005;49:3624-3630.
30. Li J, Tumidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:781-785.
31. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005;49:3136-3146.
32. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-2662.
33. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004;54:566-569.
34. Gamacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittell M, Gallego-Lara SL, Madrazo-Osuna J. Treatment of multidrug-resistant. Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-1118.
35. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997;52:987-993.
36. Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, Wallis C. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 2001;84:432-433.
37. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-838.
38. Ishiura Y, Fujimura M, Myou S, Nobata K, Liu Q, Yamamori C, Amemiya T. In vivo airway eosinophil accumulation induced by polymyxin-B reduces bronchial responsiveness in guinea pigs. Clin Exp Allergy 2001;31:644-651.
39. Voitenko VG, Bayramashvili DI, Zebrev AI, Zinchenko AA. Relationship between structure and histamine releasing action of polymyxin B and its analogues. Agents Actions 1990;30:153-156.
40. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant. Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000;162:328-330.
41. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-R59.
42. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005;41:754-757.
43. Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1964;23:552-574.
44. Berg JR, Spilker CM, Lewis SA. Effects of polymyxin B on mammalian urinary bladder. J Membr Biol 1996;154:119-130.
45. Berg JR, Spilker CM, Lewis SA. Modulation of polymyxin B effects on mammalian urinary bladder. Am J Physiol 1998;275:F204-F215.
46. Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 2004;286:C913-C922.
47. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003;37:e154-e160.
48. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003;7:R78-R83.
49. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-1011.
50. Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, Venditti M, Esposito S, Nicastri E. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005;11:682-683.
51. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005;5:1.
52. Berlana D, Llop JM, Fort E, Badia MB, Jodar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005;62:39-47.